Osteoprotegerin and its cognate ligand: A new paradigm of osteoclastogenesis

European Journal of Endocrinology

Volumn 139, Issue 2, 1998, Pages 152-154

  Hofbauer, Lorenz C ^a   Heufelder, Armin E ^b  

^a MAYO CLINIC   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE RECEPTOR; GLYCOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 11; LIGAND; MESSENGER RNA; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR RECEPTOR; VITAMIN D;

BONE MASS; CELL DIFFERENTIATION; DENDRITIC CELL; GENE EXPRESSION; HUMAN; LIGAND BINDING; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN FAMILY; SHORT SURVEY; STROMA CELL; T LYMPHOCYTE ACTIVATION;

EID: 0031869001     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1390152     Document Type: Short Survey

References (11)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 309-319.
2. Yasuda H, Shima N, Nakagawa N, Mochizuki S-I, Yano K, Fujise N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/ OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998 39 1329-1337.
3. Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997 204 35-46.
4. Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. Journal of Biological Chemistry 1998 273 5117-5123.
5. Tsuda E, Goto M, Mochizuki S-I, Yano K, Kobayashi F, Morinaga T et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochemical and Biophysical Research Communications 1997 234 137-142.
6. Miyamoto A, Kunisada T, Hemmi H, Yamane T, Yasuda H, Miyake K et al. Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. Biochemical and Biophysical Research Communications 1998 242 703-709.
7. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 165-176.
8. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S-I et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the USA 1998 95 3597-3602.
9. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells. Journal of Biological Chemistry 1997 272 25190-25194.
10. Anderson MA, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997 390 175-179.
11. Sharrock WJ, for the Organizers and Speakers. Bone and the hematopoietic and immune systems: a report of the proceedings of a scientific workshop. Journal of Bone and Mineral Research 1998 13 537-543.